Melanoma News and Highlights You Don’t Want to Miss

We know staying informed about melanoma research and treatments is important to you. That’s why we’ve put together some of our latest and most engaging articles — all in one place to make it easier for you to explore and learn at your own pace.
Featured Articles
Nivolumab at Micro-Doses Works Better Than Chemotherapy Against Relapsed Cancer
Discover how low doses of nivolumab are showing promising results compared to traditional chemotherapy for relapsed melanoma.
The Time of Day Pembrolizumab Is Administered May Link to Patient Survival
Learn about new research suggesting that the timing of pembrolizumab treatment could affect patient outcomes.
Three New Immunotherapy Agents Tested Against Melanoma in Phase 2 Clinical Trials
Get the latest on three promising immunotherapy drugs currently being tested in clinical trials for melanoma treatment.
Genetic Test: A Potential Alternative to Sentinel Lymph Node Biopsy
Explore how genetic testing might offer a less invasive option compared to traditional lymph node biopsies.
New Therapy in Clinical Trial Returns Immunotherapeutic Activity to Resistant Melanoma
Find out about a new treatment under trial that could help overcome resistance to immunotherapy in melanoma patients.
Results Prove Immunotherapy Should Be the Initial Treatment for BRAF-Mutant Tumors
Discover evidence supporting immunotherapy as the first-line treatment for tumors with BRAF mutations.
Want to Learn More?
If you have questions or want to explore additional melanoma resources, please explore our Melanoma Learning Center.
Stay Connected
Don’t miss out on important updates! Sign up for our newsletter to get the latest melanoma news and stories delivered right to your inbox.
Recent Posts

Empowering Women in Melanoma: A Look Inside the Women in Melanoma Initiative

Melanoma News and Highlights You Don’t Want to Miss

Coping with Cancer: DBT Skills for Emotional Resilience

May in Review: A Marathon Month of Melanoma Awareness, Education, and Community
